These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 23319538)

  • 1. Vaccination site and risk of local reactions in children 1 through 6 years of age.
    Jackson LA; Peterson D; Nelson JC; Marcy SM; Naleway AL; Nordin JD; Donahue JG; Hambidge SJ; Balsbaugh C; Baxter R; Marsh T; Madziwa L; Weintraub E
    Pediatrics; 2013 Feb; 131(2):283-9. PubMed ID: 23319538
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prospective assessment of the effect of needle length and injection site on the risk of local reactions to the fifth diphtheria-tetanus-acellular pertussis vaccination.
    Jackson LA; Starkovich P; Dunstan M; Yu O; Nelson J; Dunn J; Rees T; Zavitkovsky A; Maus D; Froeschle JE; Decker M
    Pediatrics; 2008 Mar; 121(3):e646-52. PubMed ID: 18310184
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Injection site and risk of medically attended local reactions to acellular pertussis vaccine.
    Jackson LA; Yu O; Nelson JC; Dominguez C; Peterson D; Baxter R; Hambidge SJ; Naleway AL; Belongia EA; Nordin JD; Baggs J;
    Pediatrics; 2011 Mar; 127(3):e581-7. PubMed ID: 21300679
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pertussis vaccine effectiveness among children 6 to 59 months of age in the United States, 1998-2001.
    Bisgard KM; Rhodes P; Connelly BL; Bi D; Hahn C; Patrick S; Glodé MP; Ehresmann KR;
    Pediatrics; 2005 Aug; 116(2):e285-94. PubMed ID: 16061582
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A population-based, postlicensure evaluation of the safety of a combination diphtheria, tetanus, acellular pertussis, hepatitis B, and inactivated poliovirus vaccine in a large managed care organization.
    Zangwill KM; Eriksen E; Lee M; Lee J; Marcy SM; Friedland LR; Weston W; Howe B; Ward JI
    Pediatrics; 2008 Dec; 122(6):e1179-85. PubMed ID: 19047220
    [TBL] [Abstract][Full Text] [Related]  

  • 6. An adolescent-adult formulation tetanus and diptheria toxoids adsorbed combined with acellular pertussis vaccine has comparable immunogenicity but less reactogenicity in children 4-6 years of age than a pediatric formulation acellular pertussis vaccine and diphtheria and tetanus toxoids adsorbed combined with inactivated poliomyelitis vaccine.
    Langley JM; Predy G; Guasparini R; Law B; Diaz-Mitoma F; Whitstitt P; Tapiero B; Dionne M; Tomovici A; Mills E; Halperin SA
    Vaccine; 2007 Jan; 25(6):1121-5. PubMed ID: 17045366
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Assessment of nine candidate DTP-vaccines with reduced amount of antigen and/or without adjuvant as a fourth (booster-) dose in the second year of life.
    Knuf M; Habermehl P; Faber J; Bock HL; Sänger R; Bogaerts H; Clemens R; Schuind A; du Prel JB; Schmitt HJ
    Vaccine; 2006 Jul; 24(27-28):5627-36. PubMed ID: 16740348
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Simultaneous vaccination of Chinese applicants for a United States immigrant visa.
    Hua L; Hongtao H; Shunqin W; Jinping G; Jiandong C; Zhaoliang L; Xinwen F
    Travel Med Infect Dis; 2008 May; 6(3):130-6. PubMed ID: 18486068
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunogenicity and safety of an inactivated hepatitis A vaccine when coadministered with Diphtheria-tetanus-acellular pertussis and haemophilus influenzae type B vaccines in children 15 months of age.
    Trofa AF; Klein NP; Paul IM; Michaels MG; Goessler M; Chandrasekaran V; Blatter M
    Pediatr Infect Dis J; 2011 Sep; 30(9):e164-9. PubMed ID: 21494175
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Diphtheria-tetanus-acellular pertussis and inactivated poliovirus vaccines given separately or combined for booster dosing at 4-6 years of age.
    Black S; Friedland LR; Ensor K; Weston WM; Howe B; Klein NP
    Pediatr Infect Dis J; 2008 Apr; 27(4):341-6. PubMed ID: 18316985
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Adapting group sequential methods to observational postlicensure vaccine safety surveillance: results of a pentavalent combination DTaP-IPV-Hib vaccine safety study.
    Nelson JC; Yu O; Dominguez-Islas CP; Cook AJ; Peterson D; Greene SK; Yih WK; Daley MF; Jacobsen SJ; Klein NP; Weintraub ES; Broder KR; Jackson LA
    Am J Epidemiol; 2013 Jan; 177(2):131-41. PubMed ID: 23292957
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Adverse reactions to diphtheria, tetanus, pertussis-polio vaccination at 18 months of age: effect of injection site and needle length.
    Ipp MM; Gold R; Goldbach M; Maresky DC; Saunders N; Greenberg S; Davy T
    Pediatrics; 1989 May; 83(5):679-82. PubMed ID: 2717284
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The risk of immune thrombocytopenic purpura after vaccination in children and adolescents.
    O'Leary ST; Glanz JM; McClure DL; Akhtar A; Daley MF; Nakasato C; Baxter R; Davis RL; Izurieta HS; Lieu TA; Ball R
    Pediatrics; 2012 Feb; 129(2):248-55. PubMed ID: 22232308
    [TBL] [Abstract][Full Text] [Related]  

  • 14. New combination vaccines: DTaP-IPV (Kinrix) and DTaP-IPV/Hib (Pentacel).
    Johns TL; Hutter GE
    Ann Pharmacother; 2010 Mar; 44(3):515-23. PubMed ID: 20197476
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antibody persistence after a primary series of a new DTaP-IPV-Hep B-PRP-T combined vaccine or separate DTaP-IPV//PRP-T and hepatitis B vaccines at 2, 4, and 6 months of age and the effect of a subsequent DTaP-IPV//PRP-T booster vaccination at 18 months of age in healthy Argentinean infants.
    Tregnaghi M; Zambrano B; Santos-Lima E
    Pediatr Infect Dis J; 2012 Jan; 31(1):e24-30. PubMed ID: 22157567
    [TBL] [Abstract][Full Text] [Related]  

  • 16. An open-label, randomized, multi-center study of the immunogenicity and safety of DTaP-IPV (Kinrix™) co-administered with MMR vaccine with or without varicella vaccine in healthy pre-school age children.
    Klein NP; Weston WM; Kuriyakose S; Kolhe D; Howe B; Friedland LR; Van Der Meeren O
    Vaccine; 2012 Jan; 30(3):668-74. PubMed ID: 22064267
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunogenicity and safety of a combination diphtheria, tetanus toxoid, acellular pertussis, hepatitis B, and inactivated poliovirus vaccine coadministered with a 7-valent pneumococcal conjugate vaccine and a Haemophilus influenzae type b conjugate vaccine.
    Pichichero ME; Bernstein H; Blatter MM; Schuerman L; Cheuvart B; Holmes SJ;
    J Pediatr; 2007 Jul; 151(1):43-9, 49.e1-2. PubMed ID: 17586189
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunogenicity and safety of an inactivated hepatitis A vaccine administered concomitantly with diphtheria-tetanus-acellular pertussis and haemophilus influenzae type B vaccines to children less than 2 years of age.
    Nolan T; Bernstein H; Blatter MM; Bromberg K; Guerra F; Kennedy W; Pichichero M; Senders SD; Trofa A; Collard A; Sullivan DC; Descamps D
    Pediatrics; 2006 Sep; 118(3):e602-9. PubMed ID: 16950952
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prevention of pertussis among adolescents: recommendations for use of tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis (Tdap) vaccine.
    America Academy of Pediatrics Commitee on Infectious Diseases
    Pediatrics; 2006 Mar; 117(3):965-78. PubMed ID: 16382131
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combination vaccine use and vaccination quality in a managed care population.
    Happe LE; Lunacsek OE; Marshall GS; Lewis T; Spencer S
    Am J Manag Care; 2007 Sep; 13(9):506-12. PubMed ID: 17803364
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.